On January 28, 2026, the U.S. Food and Drug Administration cleared Life Biosciences' Investigational New Drug (IND) application for ER-100 — a gene therapy using an adeno-associated virus vector to deliver three Yamanaka transcription factors, OCT4, SOX2, and KLF4 (OSK), for controlled, partial epigenetic reprogramming in retinal ganglion cells. The clearance marks the first human clinical trial of partial epigenetic reprogramming for cellular rejuvenation in any disease indication.
The Phase 1 trial (NCT07290244) focuses on safety and tolerability in adults with primary open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), with vision assessments as secondary endpoints. Enrollment begins Q1 2026, starting with dose escalation in OAG patients followed by expansion in NAION — ClinicalTrials.gov NCT07290244.
🔬 Key Finding
ER-100 Trial at a Glance
- Therapy Name
- ER-100
- Developer
- Life Biosciences
- IND Clearance
- January 28, 2026 (FDA)
- Trial ID
- NCT07290244
- Phase
- Phase 1 — First-in-Human
- Vector
- AAV2 (adeno-associated virus serotype 2)
- Payload
- Inducible OSK (OCT4, SOX2, KLF4)
- Delivery Route
- Single intravitreal injection
- Induction
- Systemic doxycycline (oral)
- Target Cells
- Retinal ganglion cells (RGCs)
- Indications
- Primary open-angle glaucoma (OAG) & NAION
- Enrollment Start
- Q1 2026 — dose escalation in OAG first
- Data Readout
- Q4 2026 (anticipated)
- Primary Endpoint
- Safety & tolerability
- No c-MYC
- OSK only — oncogenic risk reduced vs. OSKM
1. What the FDA Cleared in the IND Application
The FDA authorized ER-100 as an investigational epigenetic therapy candidate for age-related optic neuropathies, permitting Life Biosciences to proceed with first-in-human dosing under the trial protocol.
Cleared IND — Key Elements
- •Vector & Payload: Modified AAV2 vector delivering inducible OSK (OCT4, SOX2, KLF4) genes.
- •Mechanism: Controlled OSK expression restores methylation patterns and gene function in aged or damaged RGCs.
- •Administration: Single intravitreal injection with systemic oral doxycycline for induction control.
- •Indications: Primary open-angle glaucoma (OAG) and NAION.
- •Design: Phase 1 first-in-human, single-dose, sequential cohorts — dose escalation in OAG, then expansion in NAION.
The clearance follows preclinical data in mice and non-human primates showing restored vision, increased nerve axon survival, and improved electrical signaling without altering genomic DNA — per Life Biosciences platform data.
2. ER-100 Delivery and Partial Reprogramming Mechanism
ER-100 uses an AAV2-OSK construct to express OCT4, SOX2, and KLF4 transiently under doxycycline (Dox) control. OSK expression switches on via oral doxycycline and ceases when withdrawn — giving clinicians direct control over the reprogramming window.
This partial reprogramming approach:
- Modifies DNA methylation patterns without triggering full cellular dedifferentiation.
- Targets retinal ganglion cells (RGCs) affected by aging, pressure, or ischemic injury.
- Deliberately excludes c-MYC, reducing oncogenic potential vs. full OSKM protocols.
📊 Clinical Data
- ✓ Restored vision in mouse glaucoma models
- ✓ Improved vision in naturally aged mice
- ✓ Increased nerve regeneration after optic nerve crush injury
- ✓ Enhanced visual function and axon survival in NHP NAION models
- ✓ No alteration of genomic DNA sequence confirmed
Preclinical Program by the Numbers
3
Yamanaka factors (OSK)
AAV2
Delivery vector
0
Genomic edits
2
Species studied (mouse + NHP)
3. Target Diseases: Open-Angle Glaucoma and NAION
Both conditions feature age-related retinal ganglion cell dysfunction, making them the logical first test cases for localized epigenetic rejuvenation.
Primary Open-Angle Glaucoma (OAG)
OAG involves progressive optic nerve damage from elevated intraocular pressure, producing chronic, irreversible RGC loss and visual field defects. Existing treatments address pressure but not the underlying neurodegeneration or epigenetic aging of RGCs.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NAION causes sudden, painless vision loss from reduced blood flow to the optic nerve head. It is the most common acute optic neuropathy in adults over 50, and no approved treatment exists — making it a compelling target for a regeneration-focused approach.
4. Phase 1 Trial Design and Endpoints
NCT07290244 — Trial Structure
- •Cohort 1 (OAG): Ascending single doses — safety, tolerability, maximum tolerated dose.
- •Cohort 2 (NAION): Confirmed safe dose from Cohort 1 in NAION patients.
- •Primary endpoint: Safety and tolerability of a single intravitreal dose.
- •Secondary endpoints: Immune responses, visual acuity, visual field, OCT, electrophysiology.
⚠️ Important Note
5. Preclinical Foundation Leading to IND Clearance
The IND submission was supported by a multi-year preclinical program. Key FDA data points:
- Controlled expression: Dox-regulated induction confirmed in primate retinal tissue with clean shutoff on withdrawal.
- Methylation restoration: AAV2-OSK measurably reversed age-associated methylation patterns toward a younger epigenetic signature.
- Visual recovery: Statistically significant improvement in visual acuity and electrophysiology in NHP NAION models vs. controls.
- Genomic integrity: No off-target edits, chromosomal instability, or tumor formation across all cohorts.
The company's CSO stated in the press release that primate data "provided the confidence that controlled, transient OSK expression can safely restore cellular function in the aging retina without the safety liabilities of full reprogramming."
6. Current Status and Next Steps
Phase 1 initiates Q1 2026 with site activation underway. Preliminary safety data readout is anticipated Q4 2026 per BIO Summit 2026 company presentations.
2026 Milestones
- •Q1 2026: First patient dosing — OAG Cohort 1.
- •Q2–Q3 2026: Dose escalation completion and dose selection.
- •Q3 2026: NAION cohort initiation.
- •Q4 2026: Preliminary safety and immune response readout.
- •2027: Phase 2 design decisions pending Phase 1 outcomes.
📎 Source
7. Why This Matters: The Distinction That Counts
The significance of ER-100's IND clearance lies in what it precisely is — and what it is not. This is not a systemic youth serum. It is not an FDA endorsement of age reversal. It is a targeted gene therapy, delivered to one eye, for two specific degenerative conditions, in a safety trial with no efficacy claims.
What it does establish, for the first time, is that a regulatory authority has reviewed the science of partial epigenetic reprogramming and judged it safe enough to test in humans. The Nobel Prize science behind iPSCs has taken roughly two decades to reach a first human injection. When it arrives, it arrives via an intravitreal syringe and a glaucoma patient — not a tech billionaire's longevity protocol.
This milestone connects directly to broader themes in ObjectWire's Bio-Hacking & Longevity coverage and the adjacent clinical science of immune modulation for organ longevity covered in our Eledon Pharmaceuticals (ELDN) overview.
When the first human dose of OSK arrives via intravitreal injection for glaucoma rather than a systemic youth serum, the path from Nobel discovery to clinic stays firmly on the optic nerve.